Novo Nordisk and Nanovation sign $600m deal in rare and …
WEB10 hours ago · Novo Nordisk has signed a $600m deal with NanoVation to develop genetic medicines for rare and cardiometabolic diseases.
Novo Nordisk Just Took a $530 Million Step Onto Moderna's …
WEB16 hours ago · Novo Nordisk's deal with Korro is worth a total of $530 million in funding, milestone payments, royalties, and up-front payments to get the ball rolling. That makes the agreement a meaty but ...
Novo Nordisk bets $600M biobucks on NanoVation's ability to …
WEB1 day ago · Novo Nordisk agreed to pay NanoVation up to $600 million to collaborate on programs built on technology for targeting cells outside the liver.
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian …
WEB1 day ago · Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the development of novel genetic medicines targeting cardiometabolic ...
Research Leading to Ozempic Honored by 2024 Lasker Awards
WEB1 day ago · Novo Nordisk scientists then developed GLP-1 analogs that lasted a week, which led to the semaglutide, or the diabetes drug Ozempic. It was followed by Wegovy, for obesity, which caused an average ...
Latest news - Novo Nordisk
WEB10 July 2024. Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec. Read more. News archive. Featured stories. PRODUCTION. Expanding our fill-finish capacity.
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
WEBApr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Novo Nordisk to boost output of Wegovy, Ozempic with new NC facility - CNBC
WEBJun 24, 2024 · Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy,...
News Details - Novo Nordisk
WEBMar 5, 2024 · Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW.
News Details - Novo Nordisk
WEBBagsværd, Denmark, 4 June 2021 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy™ (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management.